PICTORIAL REVIEW

Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging

Nicolò Gennaro, MD, ANDREA MARRARI, MD, SALVATORE LORENZO RENNE, MD, FERDINANDO CARLO MARIA CANANZI, MD, VITTORIO LORENZO QUAGLIUOLO, MD, LUCIA DI BRINA, MD, MARTA SCORSETTI, MD, GIOVANNA PEPE, MD, ARTURO CHITI, MD, ARMANDO SANTORO, MD, LUCA BALZARINI, MD, LETTERIO SALVATORE POLITI, MD and ALEXIA FRANCESCA BERTUZZI, MD

INTRODUCTION

Rhabdomyosarcoma (RMS) include a heterogeneous group of rare malignant mesenchymal cancers resembling skeletal muscle differentiation. They represent >50% of soft tissue tumours in paediatric age (<16 years) with an incidence of 4 cases per million/year. Conversely, the same tumours are unusual in the non-paediatric population, accounting for 11% of cancers in adolescents and only 1–2% in the adult population.

Imaging plays a major role in the management of RMS through a comprehensive diagnostic assessment that includes extent of the primary tumour, the nodal status, image-guided biopsy, evaluation of treatment response and follow-up. Similarly to other oncohaematological diseases, hybrid imaging including PET/CT and PET/MR improves such evaluation through metabolic insights of tumour biology. The aim of this paper is to provide a comprehensive review of the imaging of adult RMS correlated with the clinicopathological characteristics, focusing on the growing role of hybrid PET-based imaging.
and pleomorphic RMS are graded according to the Fédération Nationale des Centres de Lutte le Cancer (FNCLCC) grading system, which accounts for tumour differentiation, mitosis and necrosis. aRMS and eRMS display a more easily recognisable rhabdomyoblastic differentiation than sclerosing/spindle cell and pleomorphic subtypes, defined by immunohistochemical positivity for desmin, myogenin or MYOD1. eRMS is characterised by the admixture of cellular and myxoid areas, wherein cells present eccentric vesicular nuclei and eosinophilic cytoplasm (Figure 2a–b). aRMS is composed of primitive cells with monomorphic round nuclei and owes its name to the collagenous septa that separate tumour cells into discrete nests, resembling lung alveoli (Figure 2c–d). Gene translocations involving Pax3 or seven and FOX01 are identified in most alveolar RMS, which are called “fusion-positive”. Spindle cell/sclerosing RMS represents a spectrum of RMS variants that share spindle cell morphology, including emerging entities with unique molecular and genetic features, such as VGLL2/NCOA2 and TFCP2 rearrangement or MYOD1 mutation (Figure 2e–f). Pleomorphic RMS is a less-differentiated histological variant composed of sheets of large, atypical, and multinucleated polygonal eosinophilic cells or undifferentiated round-to-spindle cells (Figure 2g–h).

Clinical features of adult RMS
The prevalent histology in adults is the pleomorphic subtype, which is extremely rare in the paediatric population. Pleomorphic subtype accounts for more than 50% of adult RMS and increases in incidence with age. Although RMS can arise at any anatomical site, adult RMS are typically localised in the extremities (40%) (Figure 3), head and neck (30%) (Figure 4) and...
RMS usually presents with an asymptomatic mass or with signs and symptoms related to the mass effect upon adjacent structures. Compared to paediatric eARMS and aRMS, clinical presentation is more aggressive with more than 30% patients presenting regional lymph node involvement and 20% patients diagnosed with distant metastasis (Figure 6).7,8 Also, specific gene expression is peculiar in the adult population with respect to the younger, suggesting adult RMS to be a separate entity in the RMS landscape.9 Unlike paediatric RMS, adult RMS is seldom, if ever, part of syndromic or familiar conditions such as hereditary retinoblastoma, neurofibromatosis Type 1, Li–Fraumeni and Costello syndromes.7 In terms of clinical outcome, the 5-year survival rate in adults is considerably poor compared to children (27% vs 70%), even if considering localised disease only (47% vs 81%).10 The reasons for such worse outcomes remain largely unknown. The intrinsic differences in tumour biology, the rarity of RMS in adult oncology, and the inability to use intensive and prolonged chemotherapy regimens as for paediatric patients have been appointed to contribute to such unsatisfactory outcomes.10,11

Imaging of RMS

Imaging provides comprehensive diagnostic assessment of RMS mainly through contrast-enhanced MRI and CT for local and distant staging, respectively.

However, ultrasound can be used to guide core-needle biopsy of superficial lesions (Figure 7) and may identify superficial or bulky deep-seated lymphadenopathy (Figure 8). Notably, ultrasound may provide better disease assessment in rare presentations, like thyroid RMS (Figure 9).

MRI is the imaging modality of choice for local staging of RMS due to its excellent contrast resolution for soft tissues (Figure 10). RMS appears iso- to slightly hypointense to skeletal muscle on $T_1$ weighted sequences, due to the hyaline collagenuous stroma and slightly-to-markedly hyperintense on $T_2$/STIR-weighted sequences, depending on the amount of necrohaemorrhagic content. Following intravenous gadolinium contrast administration, RMS shows moderate-to-avid heterogeneous enhancement due to internal necrotic components. Necrosis is usually visualised as hypodense and hyperintense areas on CT and fluid sensitive MRI sequences, respectively (Figure 11). MRI also estimates tissue cellularity through the apparent diffusion coefficient (ADC), obtained with diffusion-weighted imaging (DWI). Such assessment can be valuable to confirm necrosis (usually

Figure 3. Non-enhancing areas representing necrotic tissue (arrow) on post-contrast $T_1$ W image in (a) post-contrast axial $T_1$W image acquired at the level of the left thigh in a 39 year-old male diagnosed with pleomorphic RMS; (b) sagittal post-contrast $T_1$ weighted image of the right thigh of a 49-year-old male diagnosed with spindle cell/sclerosing RMS. RMS, rhabdomyosarcomas; $T_1$W, $T_1$ weighted.

Figure 4. 19-year-old patient diagnosed with recurrent pleomorphic RMS. $^{11}$C-Methionine PET fused with $T_2$ weighted MR images shows (a) in the sagittal and (b) coronal view of the lesion extending through the inferior temporal gyrus, middle cranial fossa, sellar region, masticatory space and pterygopalatine fossa (arrow). A central necrotic area is visible (asterisk). PET, positron emission tomography.
associated with an increase in ADC values) and may complement the assessment of tumour response after therapy, along with the early detection of local relapse after surgery.\textsuperscript{12,13} Dynamic contrast-enhanced MRI (DCE-MRI) provides complementary information to detect necrosis by displaying low wash-in/out and time-to-peak rates.\textsuperscript{13} Despite the imaging appearance of primary RMS being heterogeneous and non-specific, Allen et al outlined a radiologic-pathology correlation in a small cohort of patients.\textsuperscript{14} aRMS, spindle-cell/sclerosing and pleomorphic subtypes tend to be highly heterogeneous due to vast necro-haemorrhagic components, whilst eRMS tends to be homogeneous with minimal central necrosis.\textsuperscript{15}

In the local staging of the disease, MRI provides in-depth characterisation of the tumour relationship with surrounding organs and neurovascular bundles, which may hinder surgical resectability (Figure 12). The visualisation of peripheral nerves may possibly be complemented by echoplanar DWI with background...
body signal suppression using a single b-value (around 700 s/mm²), a technique named DW neurography (Figure 12c–d). Dedicated post-processing softwares have been recently implemented to improve the conspicuity of the nerve roots on coronal maximum intensity projection (MIP) images, which are of great utility in displaying long nerve trajectories. Moreover, quantitative diffusion tensor imaging (DTI) neurography is emerging as a complementary tool to evaluate the microarchitecture of the nerve fibers through parameters like mean diffusivity and fractional anisotropy.

Unlike most soft tissue sarcomas, regional and distant lymphadenopathies are typically encountered in RMS. They are often first detected at ultrasound and then confirmed at CT or MR, showing enlarged volume, eccentric cortical thickening and internal vascularised nodules or septa (Figure 13).

Distant metastases at diagnosis occur in more than 20% and are mostly located in the lungs. CT or PET/CT are therefore the modalities of choice for distant staging (Figure 14). In this respect, a maximum diameter exceeding 5 mm is usually considered the cut-off value to consider a pulmonary nodule as a likely metastasis in high-grade sarcomas. CT also provides high accuracy in assessing lytic cortical bone lesions and therefore complements the intramedullary bone assessment at MRI. Brain metastases are relatively rare and head contrast-enhanced MRI is required only in patients with neurologic symptoms.

**PET and the added value of hybrid imaging**

High-grade soft tissue sarcomas are mostly characterised by high mitotic count sustained by intense glycolytic activity. Hence, they can be well-displayed at 18F-FDG PET, appearing as a hypermetabolic area with high radiopharmaceutical uptake. Although clinical applications of hybrid imaging in soft tissue sarcoma are potentially numerous, PET-based imaging is not routinely used for staging soft tissue sarcoma. In fact, CT and MRI usually meet the needs of an accurate local and distant staging. However, the typical nodal, bone and bone marrow involvement encountered in RMS makes PET-based imaging of particular importance in the comprehensive evaluation of this disease. Solid evidence suggests whole-body 18F-FDG PET/CT to represent the preferred staging and re-staging modality for RMS.
outperforming conventional imaging (CT, MRI, bone scintigraphy) in the assessment of local, regional and distant disease (86% vs 54% accuracy, respectively). A recent review confirmed this evidence, reporting PET/CT to change the management of RMS patients in 18% of cases.\textsuperscript{20}

PET-based assessment is critically useful for the identification of regional or distant lymphatic spread. \textsuperscript{18}F-FDG PET/CT detects lymph node involvement with 80–100% sensitivity and 89–100% specificity (Figure 15).\textsuperscript{21} Nodal disease at diagnosis represents biological aggressiveness and is either the strongest predictive factor for failure of local tumour control and an independent negative prognostic factor of shorter 5-year overall survival.\textsuperscript{21,22}

PET outperformed bone scintigraphy imaging in the assessment of bone involvement, which reduces 3-year event-free survival from 34 to 14%.\textsuperscript{20} Possible explanations are that \textsuperscript{18}F-FDG-PET/CT...
CT and bone scintigraphy rely on different mechanisms to detect tumour involvement. Whereas the first directly visualises the glucose uptake within the tumour, scintigraphy indirectly images the neoplastic involvement by displaying tumour-induced bone repair and remodelling. Such intrinsic differences may also significantly underestimate or overestimate the tumour response, considering that changes in bone structure in response to therapy can take several months to occur.23 The high diagnostic accuracy of PET imaging may also possibly overcome the need for a bone marrow biopsy, which is still currently used for the definition of staging and prognosis (Figure 16).

When imaging tumours in the head and neck area, the high physiological uptake of 18F-FDG within the brain represents an important limitation particularly in the evaluation of intracranial infiltration. In an effort to overcome such drawbacks, other radiopharmaceuticals like 11C-methionine (Figures 4 and 13) and 11C-choline have been introduced for the imaging of skull base, head, neck and brain tumours.24 Similarly to 18F-FDG PET, 11C-choline PET/CT was shown to be superior to CT, MRI and scintigraphy in the assessment of local, regional and distant disease stage (94% vs 50% accuracy, respectively), especially lymph node and bone disease. Moreover, it increased specificity in detecting lung metastases.25 Detection of lymph node involvement is further refined when 11C-choline PET/CT is used instead of conventional imaging (100% vs 63% accuracy, respectively). In the detection of recurrent tumours, PET/CT may play a complementary role to MRI in discriminating local tumour recurrence from post-therapeutic tissue changes, especially when peritumoral oedema is present.26 Unlike PET/CT, PET/MRI is still a rarity in the clinical scenario. This notwithstanding, it is possible to combine PET and MRI acquired separately at different times, although motion artefacts and partial volume effects may alter the quality of the final imaging.27

Radiotherapy takes considerable benefit from PET/MRI, since the combination of the two provides better delineation of ill-defined tumours for treatment planning.28 Moreover, the exquisite anatomic details and the functional insights of tumour biology provided by both PET and MRI may improve the assessment of soft tissue distant metastases (Figure 17).

Despite its clinical use still being limited, PET/MRI has the potential to provide further improvement in the functional evaluation of tumour changes after therapy and represent a substantial benefit in the management of RMS in adolescent and adult patients, given that the estimated cumulative radiation dose is nearly five times lower than PET/CT.29 The main limitations of PET-based hybrid imaging are false-positive reactive lymph nodes – a common finding in regional lymph nodes after percutaneous biopsy, and true-positive metastatic lymph nodes located close to sites of physiologic high radiotracer accumulation (urinary bladder, brain, and heart in case of 18F-FDG).30
Treatment of adult RMS
Given its rarity and complexity, the management of adult RMS should be centralised in selected centres with a multidisciplinary expertise in sarcoma.31

The introduction of intense, multidrug regimens has contributed to substantial improvements in the prognosis of RMS patients. In fact, like other small round cell tumours, aRMS and eRMS are chemosensitive tumours with more than 85% dimensional response according to RECIST 1.1.7 Chemotherapy thus represents a first-line approach even in the case of localised RMS, also considering the high risk of systemic spread at initial diagnosis. Unlike paediatric patients, which are treated with different chemotherapy regimens according to specific risk categories,32 aRMS and eRMS are always treated with high-dose multidrug combinations including vincristine, doxorubicin, ifosfamide, and etoposide. Local treatment varies according to tumour location and response to chemotherapy. When feasible, surgery aims to achieve radical excision through a wide resection with adequate tumour margins. Radiation therapy can be delivered both in a pre-/post-operative setting, but pre-operative RT (alone or combined with chemotherapy) is preferred since the treatment field size is smaller, reduces tumour cellularity, and allows downstreaming of disease. However, considering the high radiosensitivity of RMS, it may also represent the exclusive treatment modality for local control when demolitive surgery is not an option. Regional lymphadenectomy or irradiation should always be performed in case of positive nodes.33

The management of the pleomorphic RMS diverges considerably from aRMS and eRMS variants due to its poor chemo/radio-sensitivity. Surgery followed by radiation therapy represents the standard treatment, but pre-operative doxorubicin-based chemotherapy may possibly be considered when surgery is not feasible. Finally, the spindle cell/sclerosing variant is generally treated with surgery and/or exclusive radiation therapy given the limited chemosensitivity.

Radiation therapy and/or percutaneous treatments, like cemotoplasty or ablation, represent an effective option to treat oligometastatic patients or achieve rapid pain relief in symptomatic patients (Figure 16).34,35

FUTURE TRENDS IN IMAGING
The recent trends in imaging research of RMS include assessing the role of functional imaging (DCE-MRI, DWI and PET) in the prediction of tumour response after neoadjuvant therapies and in the early identification of tumour recurrence.20 Unraveling the predictive value of ADC and SUV is an intriguing task, especially when areas of photopenic 18F-FDG uptake coincide on areas characterised by low ADC values.36 Absolute parameters extracted from DWI and intravoxel incoherent motion (IVIM) have recently been correlated with Ki67 proliferation index in murine models of RMS, representing a further step in the awareness of biological information enclosed in diffusion based imaging.37 In a preclinical setting, PET tracers like 18F-FAPA PET and 18F-FMISO are promising labelled-molecules reflecting tumour hypoxia, which would encourage radiotherapy escalation through hypoxic radiosensitisers or identification of areas requiring radiotherapy boost.38 Being conventional imaging still far from providing an accurate histological characterisation in sarcoma patients, advanced image analysis is showing promising results in the differential diagnosis of RMS and may complement the information coming from conventional imaging and histology. In this regard, a deep-learning-based computer-aided diagnosis (CADx) system was able to discriminate embryonal from alveolar RMS solely by analysing multi parametric MR images.39 Recent early clinical experiences using 68Ga-Ga-DOTA-FAPI-04 PET/CT have reported a better sensitivity and accuracy for the detection of both primary and metastatic lesions than did 18F-FDG PET/CT. As 68Ga-Ga-DOTA-FAPI-04 PET/CT strongly accumulates in those cancers characterised by a prominent desmoplastic reaction, soft tissue sarcoma resulted among the tumours with the highest uptake. With regard to RMS, this new radiotracer seems particularly promising as it was shown to be superior to 18F-FDG PET/CT both in the nodal staging and in the detection of bone metastasis.40,41

CONCLUSIONS
An effective collaboration between clinicians and radiologists in referral sarcoma centres bears the potential to guide the clinical management of adult RMS. Besides morphological assessment through conventional cross-sectional imaging, hybrid imaging combining PET with CT or MRI has been established as a reliable tool to better define the extent of adult RMS, especially with regard to lymph node and bone marrow involvement. In light of recent developments in hybrid imaging, the radiological characterisation of tumour response after treatment and its correlation with clinical outcome represents an ambitious goal to personalise multimodal treatment in an extremely rare cancer like adult RMS.

REFERENCES
2. van der Graaf WTA, Orbach D, Judson I, Ferrari A. Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. Lancet Oncol 2017; 18: e166–75. doi: https://doi.org/10.1016/S1470-2245(17)30099-2
Hybrid Imaging of Adult Rhabdomyosarcoma

Cancer 1984; 33: 37–42. doi: https://doi.org/10.1002/1097-0214.33030108


